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Hypothesis: Aim of the study was to quantify ERCC1, RRM1, and
TopoII mRNA expression profile as predictive factors for response
and survival in SCLC patients treated with platinum/etoposide.
Methods: Total RNA was extracted from microdissected sections of
103 formalin-fixed, paraffin embedded biopsies. Relative quantifi-
cation was performed by real-time polymerase chain reaction (PCR)
using intron-spanning probes.
Results: Eighty-five samples (83%) were successfully amplified.
Median overall survival (OS) was 9.9 months; 45 patients had
limited disease (LD) (OS 13.1) and 40 had extensive disease (ED)
(OS  7.1). Fifty-six (65%) patients had an objective response to
treatment. A gene expression was detectable in all samples and a
correlation between ERCC1 and RRM1 (Rs  0.34, p  0.0011)
was found. According to response to treatment, it was found that
lower TopoII expression was associated to a better response in LD
patients (p  0.025) and, more interestingly, those who had a
complete response had lower TopoII than both partial and nonre-
sponsive patients (p  0.015). At univariate analysis LD patients
with low ERCC1 had significantly longer survival (median survival
14.9 versus 9.9, p  0.012), whereas RRM1 and TopoII levels
showed no influence on outcome. At the multivariate analysis,
ERCC1 was confirmed to be an independent prognostic factor for
survival in LD patients. No significant role was found for ERCC1,
RRM1 and TopoII in ED patients.
Conclusions: ERCC1 and TopoII are candidate markers in pre-
dicting clinical outcome and response to treatment in LD SCLC
patients and are worth of further investigation in a prospective study.
Key Words: Excision repair cross-complementing 1 gene, Ribonu-
cleotide reductase M1 gene, Topoisomerase II gene, Small-cell
lung cancer, Pharmacogenomics.
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Small-cell lung cancer (SCLC) accounts for about 15% ofall cases of lung cancer, it is characterized by rapid growth
and early extrathoracic spread1 and cytotoxic chemotherapy
is the cornerstone of any therapeutic strategy. The combination
of a platinum compound (cisplatin or carboplatin) with etopo-
side is currently considered the standard of care for both exten-
sive (ED) and limited disease (LD), and in the latter usually in
combination with concurrent or sequential thoracic radiotherapy.
Even if considerable tumor shrinkage is usually observed in
more than 80% of cases, almost invariably patients die of the
relapse or recurrence of the neoplastic disease.2,3
Excision repair cross-complementing 1 (ERCC1) gene
is a structure-specific DNA repair endonuclease required to
resolve DNA interstrand crosslink-induced double-strand
breaks.4 This enzyme belongs to nucleotide excision repair
(NER) system and has been extensively investigated because of
its ability to repair platinum intrastrand DNA adducts.5 The
expression levels of ERCC1 transcripts have been associated
with survival in cancer patients treated with cisplatin-based
chemotherapy, as consistently reported in different in vitro and
in vivo cancer models, as in ovarian,6 gastric adenocarcinomas,7
colorectal,8 esophageal,9 and in non-small cell lung cancer
(NSCLC).10,11 Similar results have also been reported in the
evaluation of ERCC1 single nucleotide polymorphisms
(SNPs).12–14 Recently, a retrospective study showed a predictive
role for ERCC1 protein expression (detected by immunohisto-
chemistry) in NSCLC patients treated with adjuvant cisplatin-
based adjuvant chemotherapy.15
Ribonucleotide reductase M1 (RRM1) gene codes for
an enzyme necessary for DNA synthesis, catalyzing the
biosynthesis of deoxyribonucleotides. Different investigators
showed that up-regulation of RRM1 mRNA levels are gen-
erally associated with chemoresistance to gemcitabine-based
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therapies.16,17 This drug has been recently tested in SCLC, in
front- as well as in second line therapies.18,19 RRM1 has also
been proposed as a good candidate gene with metastatic
suppressor activity because of its localization in a chromo-
somal region frequently deleted in lung cancer.20 A signifi-
cant correlation between RRM1 and ERCC1 in terms of
transcript levels11 has also been previously reported in
NSCLC patients treated with cisplatin and gemcitabine.
DNA topoisomerase II (TopoII) is a 170KD ubiqui-
tous enzyme markedly up-regulated in proliferating cells,
catalyzing the ATP-dependent breakage and rejoining of DNA
double strand, and represents the molecular target for many
anticancer drugs called TopoII-inhibitors. The role of TopoII
enzymes in drug resistance has been already investigated and an
increased activity, without any alteration of expression, was
initially detected in cisplatin-resistant cell lines.21 Conversely, in
SCLC a significantly higher TopoII expression compared with
NSCLC was reported and it was correlated to the higher che-
mosensitivity.22 Other studies reported an up-regulation of To-
poII in cisplatin-resistant SCLC cell lines and a significant
TopoII down-regulation in SCLC cells resistant to etoposide, a
TopoII-inhibitor drug.23 Additionally, low TopoII immunore-
activity was found to be associated with better survival in SCLC
patients receiving different drug combinations, including cispla-
tin and etoposide.24 The significance of TopoII expression in
SCLC patients by means of transcript level quantification has
never been determined in literature.
This study aimed at retrospectively test the predictive
value on both response to treatment and survival of ERCC1,
RRM1 and TopoII mRNA levels, as detected by real-time
PCR, in a retrospective cohort of SCLC patients treated with
platinum/etoposide regimens.
PATIENTS AND METHODS
Patients and Samples
From the clinical database of patients with a diagnosis
of lung cancer and referred to the University of Torino,
Department of Clinical & Biologic Sciences, Thoracic On-
cology Unit, for cytotoxic chemotherapy, all SCLC patients
registered between January 2000 to December 2005 were
initially extracted. Out of the 183 identified patients, a subset
of 103 patients who were treated with platinum agents (cis-
platin or carboplatin) plus etoposide as a front line treatment,
were selected. Complete information regarding histopatho-
logic data, tumor stage, chemotherapy administered, and
follow-up were considered as strict inclusion criteria. The
patients not included in this subset were either treated at the
same Institution but did not receive cisplatin/carboplatin, or
were treated in outside facilities or did not have available
outpatient charts. The demographics and clinicopathologic
characteristics of the patients excluded from the study were
similar to those of the present series.
For all of the 103 patients, bronchoscopic or fine-needle
aspiration (FNA) lung biopsies were available. All material
was fixed in 4% buffered formaldehyde and embedded in
paraffin (FFPE). Five-micrometer-thick sections were cut and
stained with hematoxylin and eosin for histologic review. The
study was approved by the institutional review board of the
hospital. All samples were anonymized by a pathologist not
taking part in the study and gene expression analysis was
performed in blind of the clinicopathologic data.
Microdissection, RNA Isolation, and cDNA
Synthesis
Representative tumor areas from serial 10-m-thick
sections were selected under microscope magnification (5–
10) by nuclear Fast Red (Sigma-Aldrich, St. Louis, MO)
counterstaining, and microdissected by using a scalpel in
RNAse-free conditions.
RNA isolation was performed as previously de-
scribed.10 In brief, tissue samples were heated at 92°C for 30
minutes in 4 mol/L Dithiothreitol-Guanidine isothiocyanate/
sarcosine [4 mol/L guanidinium isothiocyanate, 50 mmol/L
Tris-HCl (pH 7.5), 25 mmol/L EDTA; Invitrogen, Carlsbad,
California]. Fifty microliter of 2 mol/L sodium acetate (pH
4.0), followed by 600 L of freshly prepared phenol/chloro-
form/isoamyl alcohol (250:50:1), were added to the tissue
suspensions. The suspension was centrifuged at 13,000 rpm
for 8 minutes in a chilled (8°C) centrifuge. The upper aque-
ous phase was removed and combined with glycogen (10 L)
and 300 to 400 L of isopropanol. The tubes were placed at
20°C for 30 to 45 minutes to precipitate the RNA. After
centrifugation at 13,000 rpm for 7 minutes in a chilled (8°C)
centrifuge, the supernatant was carefully poured off and the
pellet was resuspended in 50 L of 5 mmol/L Tris. cDNA
synthesis was performed as previously shown.25
Real-Time PCR
Relative cDNA quantitation for ERCC1, RRM1, and
TOPOII and an internal reference gene (-actin) was done
using a fluorescence-based real-time detection method [ABI
PRISM 7900 Sequence Detection System (Taqman); Applied
Biosystems, Foster City, CA] as previously described.26 The
sequences of the primers and probes used were as follows:
ERCC1 forward 5-GGGAATTTGGCGACGTAATTC-3, re-
verse 5-GCGGAGGCTGAGGAACAG-3, probe (FAM)-5-
CACAGGTGCTCTGGCCCAGCACATA-3-(TAMRA); RRM1
forward 5-ACTAAGCACCCTGACTATGCTATCC-3, reverse
5CTTCCATCACATCACTGAACACTTT-3, probe (FAM)-5-
CAGCCAGGATCGCTGTCTCTAACTTGCA-3-(TAMRA),
TOPOII forward 5-GCCAGAATCTGTTCGCTTCAAC-3, re-
verse 5-AGGAAACTGAGTGCCGGCTT-3, probe (FAM)-5-
AAGCAGCCAGGCTGCCTGTCCAG-3-(TAMRA); -ACTIN
(internal reference gene) forward 5-TGAGCGCGGCTA-
CAGCTT-3, reverse 5-TCCTTAATGTCACGCACGATTT-3,
probe (FAM)-5-ACCACCACGGCCGAGCGG-3-(TAM
RA).10,17,27 All probes used in this study were intron-spanning
to avoid genomic DNA contamination. The PCR reaction
mixture consisted 1,200 nmol/L of each primer, 200 nmol/L
probe, 200 nmol/L each of dATP, dCTP, dGTP, dTTP, 3.5
mmol/L MgCl2, and 1 Taqman Universal PCR Master mix
to a final volume of 20 L (all reagents were from PE
Applied Biosystems, Foster City, CA). Cycling conditions
were 50°C for 2 minutes, 95°C for 10 minutes, followed by
46 cycles at 95°C for 15 seconds and 60°C for 1 minute. Gene
expression levels are expressed as ratios (differences between
the Ct values) between two absolute measurements (genes of
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interest/internal reference gene). Total RNAs (Stratagene, La
Jolla, CA) was used as control calibrator on each plate.
Statistical Methods
To test significant associations between the continuous
variable “gene expression” and dichotomous variables (pa-
tient’s age, sex, tumor stage, etc.) the Mann-Whitney U test
and Kruskal-Wallis test were used. Spearman’s correlation
coefficients were calculated to estimate the correlation be-
tween mRNA levels. Tumors were dichotomized into groups
with high or low mRNA expression for each gene according
to cut-off values (median values of expression) and the
relationship between groups and response to treatment was
analyzed by the 2 test. Kaplan-Meier survival curves and the
Cox-Mantel log-rank test were used to analyze univariate
distributions for survival. Cox’s proportional hazards multi-
variate analysis was used to evaluate which of the factors
significant at the univariate analysis had a significant influ-
ence on survival. Statistical significance was set at p  0.05.
RESULTS
Patients’ Characteristics
Out of the 103 selected cases, 18 samples (17%) were
not successfully amplified because of the low amount of
viable tumor cells and/or the extensive necrosis. No differ-
ences concerning clinicopathologic parameters were ob-
served in the excluded cases compared with the 85 cases
analyzed. Table 1 shows the relevant characteristics of all
patients included in the study (n  85). Median age was 63
years with a 74% male population. Forty-five patients (53%)
had LD at the time of diagnosis. Staging system used in this
study was the two-stage system proposed by the International
Association for the Study of Lung Cancer.28
All patients received etoposide (100 mg/m2, days 1–3),
54 (64%) in combination with cisplatin (80 mg/m2, day 1)
whereas the remaining were treated with carboplatin (AUC
6). For the purpose of this study, the objective response rate
to chemotherapy after two cycles in all patients was consid-
ered and 56 (65%) patients showed an objective (complete or
partial) response (limited disease  68%, extensive dis-
ease  63%). Those patients with stable or progressive
disease (35%) were considered nonresponders. Most patients
(38 out of 45) with LD received sequential radiotherapy (total
RT dose 45 Gy) and 4 out of 40 patients with ED received
palliative radiotherapy.
ERCC1, RRM1, and TopoII mRNA Levels
in SCLC
Gene expression levels were detectable in 85 samples
by means of real-time PCR on paraffin-embedded specimens
for all the three genes tested. Median relative gene expression
value was 5.3 for ERCC1 [0.5–23.4, standard deviation (SD)
3.7], 1.9 (0.1–9.6, SD  1.98) for RRM1, and 1.12 (0.1–
47.19, SD 8.6, all unit-less ratio) for TopoII. By adopting
cut-off values according to median levels of expression for
each of the three markers, no significant association between
ERCC1, RRM1, and TopoII mRNA levels and factors such
as age, sex, or stage of disease was found (all ps  0.05,
Mann-Whitney U tests).
By matching gene expression levels obtained from each
sample, a significant correlation between ERCC1 and RRM1
in the overall population of patients was detected (Spear-
man’s rank correlation method rs  0.29, p  0.01, Figure
1A). However, it was found that this association was stronger
in LD SCLC (rs  0.41, p  0.006, Figure 1B) and not
significant in ED SCLC patients (rs  0.17, p  0.27, Figure
1C). No other significant correlation between ERCC1 and
TopoII or between RRM1 and TopoII mRNA levels was
detected in any disease stage (all ps  0.05).
Gene Expression and Response to
Chemotherapy
To test if the pretreatment ERCC1, RRM1, and To-
poII mRNA level was associated with the response to
platinum/etoposide therapy, the patients were simply divided
in two groups according to response to treatment: responders
(R, n  56) and nonresponders (NR, n  29).
Table 2 shows the number of patients for each group
(transcript expression is high or low, according to median
values) in the overall population and dividing patients ac-
cording to tumor stage. The results indicate that ERCC1 and
RRM1 were not associated with response to chemotherapy
neither in the whole series nor in any disease stage, whereas
low expression of TopoII was significantly correlated to a
better response to therapy in patients with LD (p  0.025, all
2 tests). Indeed, in this subgroup of patients, four out of 14
nonresponders (28%) had low levels of TopoII compared
with 20 out of 31 (65%) in the group of responders. TopoII
expression did not provide any information in ED subgroup
of patients.
TABLE 1. Clinical Characteristics of Patients
Patients 85
Age (range) 63 (43–81)
Sex
Male 63
Female 22
PS
0 22
1 49
2 14
Stage
Limited 45
Extensive 40
Therapy
Cisplatin/etoposide 54
Carboplatin/etoposide 31
Response
CR 13
PR 43
SD 12
PD 17
Responders are those patients with complete (CR) or partial response (PR);
nonresponders are those with progressive (PD) or stable diseases (SD).
PS, performance status.
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It can also be observed that patients with limited stage
disease with a complete response (CR, n  7) had TopoII
mRNA levels significantly lower than both partial (PR, n 
24) and nonresponder (NR, n  14) patients (p  0.015,
Kruskal-Wallis test, see Figure 2). Patients with progressive
and stable disease had comparable TopoII mRNA levels.
Gene Expression and Overall Survival
To evaluate the relationship between ERCC1, RRM1,
and TopoII mRNA levels and overall survival, as well as
that of other clinical characteristics known to be associated
with survival, patients were stratified according to dichoto-
mized variables in univariate analysis.
Table 3 shows median overall survival (OS) for each
stratified variable with the Cox-Mantel log-rank and the
corresponding p values. Median OS of the 85 SCLC patients
was 9.9 months. Overall, patients with lower performance
status (PS) (p  0.0001), limited extension of disease (p 
0.0002) and with an objective response to chemotherapy (p
0.0009) had a significantly longer survival. By contrast, age,
sex, ERCC1 (see Figure 3A), RRM1, and TopoII (see
Figures 3B, C) had no significant impact on survival.
Among patients with LD SCLC (n  45) those with
low ERCC1 mRNA levels had significant longer survival
than those with high ERCC1 expression (p  0.012, Figure
3D) whereas RRM1 and TopoII levels showed no signifi-
cant influences on survival.
Furthermore, in patients with LD SCLC the Cox’s
proportional hazards multivariate analysis (reported in Table
4) showed that ERCC1 [hazard ratio (HR)  2.06, p 
0.014], PS (HR 4.86, p 0.0064), and response to therapy
(HR  2.97, p  0.0049) were independent prognostic
factors for survival, although the statistical significance re-
mains limited by the small group of patients analyzed.
DISCUSSION
Recently, pivotal studies based on molecular profiling,
including quantitative real-time PCR, microarray, and genetic
analysis of SNP, have reached promising results in different
FIGURE 1. Correlation between
ERCC1 and RRM1 mRNA levels in
(A) overall, (B) limited disease, and
(C) extensive disease patients.
TABLE 2. Relationship Between mRNA Levels and Response to Therapy
Overall Extensive Disease Limited Disease
R NR p R NR p R NR p
ERCC1 0.54 0.32 0.92
Low 27 15 11 8 16 7
High 29 14 14 7 15 7
RRM1 0.75 0.74 0.92
Low 27 15 12 8 15 7
High 29 14 13 7 16 7
TOPOII 0.22 0.93 0.025
Low 31 12 11 8 20 4
High 25 17 14 7 11 10
Relationship between mRNA levels and response to therapy. All genes’ mRNA levels were dichotomized into high and low
groups according to median level of expression. All tests are 2.
FIGURE 2. Comparison of TopoII mRNA levels determined
by real-time PCR between complete, partial, and nonre-
sponder patients. The line in the middle represents the me-
dian values. The upper and lower bars represent the 10th to
90th percentile from the median.
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tumor types, including NSCLC.29 On the other hand, very
few data have been produced in the field of SCLC, which
represents one of the most aggressive cancer types and to date
has not received significant improvements in the therapeutic
modality. In fact, ED SCLC patients have a median survival of
7 to11 months, and only 2% of them survive 5 years or more
whereas for patients with LD, the median survival is ranging
from 12 to 20 months and the 5-year survival from 12 to 17%.30
In the present study, a real-time PCR method was
applied to target three genes involved in the responsive-
ness to standard SCLC chemotherapy. Among these,
ERCC1 transcripts have been extensively investigated in
NSCLC by different authors and its expression inversely
associated with survival of patients treated with platinum-
based regimens.10,11 Similarly, some investigators showed
that RRM1 mRNA levels are associated with chemoresis-
tance to gemcitabine-based therapies16,17 and a correlation
with ERCC1 has been consistently reported in NSCLC.11
This is the first report in which the expression of the
two genes have been evaluated in SCLC. The overall results
show a correlation between ERCC1 and RRM1 gene expres-
sion but, when patients were stratified according to the
extension of the disease, only for those with LD SCLC, the
association was still maintained (Rs  0.41, p  0.001). This
could probably be the consequence of a potential transcrip-
tional deregulation resulting in disease progression from the
limited to the extensive stage, which could also explain why
all the significant findings of this work are restricted to LD
patients. Previously, RRM1 was reported to be a gene with
metastasis suppressor function in lung cancer20 and, even if
the present study failed to detect a differential expression of
RRM1 between LD and ED, an interruption of the transcrip-
tional ERCC1-RRM1 coexpression after metastatic spread
has been observed. Based on this consideration, future studies
should accurately address the regulatory mechanisms of such
genes of pharmacological interest in lung cancer.
Data from the present study cannot be directly com-
pared with those previously reported in advanced NSCLC11
because of different experimental PCR conditions. A pivotal
prospective study testing such genes (ERCC1 and RRM1)
either in NSCLC and SCLC is clearly warranted. With
regards to response to treatment, neither ERCC1 or RRM1
were correlated to clinical response, in both LD and ED
patients. However, survival analysis of patients divided into
groups by gene expression levels shows that ERCC1, but not
RRM1, is able to predict outcome of LD SCLC patients
(median overall survival 14.9 versus 9.9, p  0.012). Known
prognostic factors such as PS and response to treatment
showed a stronger impact on survival (p  0.0007 and
0.0013, respectively). However, most LD patients are re-
sponders (70%) with low PS (91%), whereas in our study, the
ERCC1 cut-off value was selected according to the median of
TABLE 3. Univariate Analysis of Survival of Overall, Limited and Extensive SCLC Patients
Overall Extensive Disease Limited Disease
MS Log-Rank p MS Log-Rank p MS Log-Rank p
Age 0.11 0.06 0.23
63 11.9 2.48 9.4 3.49 14 1.40
63 8.3 5.2 11.4
Sex 0.30 0.30 0.85
M 9.9 0.45 6.7 1.06 0.52 13.1 0.03
F 9.5 8.7 13.9
PS 0.0001 0.01 0.0007
01 10.6 23.19 8.2 6.59 14 11.5
2 6 4.2 6.2
Stage 0.0002
L 13.1 13.4
E 7.1
Response 0.0009 0.0015 0.0013
R 12.2 15.21 9.5 10.02 14.7 10.28
NR 7 5.2 8.7
ERCC1 0.093 0.68 0.012
Low 12.2 2.50 6.3 0.20 14.9 5.48
High 7.9 7.3 9.9
RRM1 0.47 0.14 0.47
Low 9.7 0.52 6.7 2.17 14 0.50
High 10.4 9.5 11.6
TOPOII 0.57 0.46 0.57
Low 9.8 0.32 7 0.83 13.9 0.32
High 10 6.7 11.4
Cox-Mantel log-rank test were used to analyze univariate distributions.
MS, median survival time of each group.
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expression levels, thus separating two groups with the same
number of patients.
The additional marker investigated, TopoII, is the
target enzyme of etoposide and the association between its
expression level and resistance to etoposide is controversial:
in vitro studies indicated that lower TopoII activity31 and
expression level23 were associated to a relative drug resis-
tance in SCLC cell lines, whereas immunohistochemical
evaluation of TopoII in paraffin embedded SCLC specimens
reported an opposite prognostic role.24 We first investigated
TopoII expression at the transcriptional level in SCLC and
demonstrated that although TopoIImRNA levels are not able to
predict the patients’ outcome, they are significantly associated to
response to platinum/etoposide in patients with LD SCLC (p 
0.025). In addition, TopoIImRNA levels were significantly lower
in patients with a complete response than those of both partial- and
nonresponder patients (p  0.015), suggesting a dose-response
relationship between Topo II expression and response to therapy.
In conclusion, this retrospective study may support the
role of ERCC1 and TopoII mRNA determination as potential
predictive factors of survival and response, respectively, partic-
FIGURE 3. Kaplan-Meier survival analysis for (A) ERCC1, (B) RRM1, and (C) TOPOII in overall population; (D) curve is
ERCC1 in limited stage patients.
TABLE 4. Multivariate Cox’s Regression Analysis in Limited
Stage Disease Population of Patients
Multivariate Analysis HR 95% CI p
ERCC1 2.06 1.18 4.38 0.014
PS 4.86 1.56 15.14 0.0064
Response to therapy 2.96 1.39 6.36 0.0049
Factors included are those significantly associated with survival at univariate level.
HR, hazard ratio; CI, confidence intervals.
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ularly in SCLC patients with limited disease. Considering the
lack of a standardization of gene quantification methods, the
validation of the result of the present study in the clinical
practice needs to be assessed in a prospective setting.
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